File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1038/jhh.2011.105
- Scopus: eid_2-s2.0-84866393077
- PMID: 205359
- WOS: WOS:000308688700001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications
Title | Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications |
---|---|
Authors | |
Keywords | atrial fibrillation prevention renin-angiotensin-aldosterone system |
Issue Date | 2012 |
Publisher | Nature Publishing Group. The Journal's web site is located at http://www.nature.com/jhh |
Citation | Journal Of Human Hypertension, 2012, v. 26 n. 10, p. 563-569 How to Cite? |
Abstract | Hypertension is one of the most important risk factors associated with atrial fibrillation (AF) and increased the risk of cardiovascular events in patients with AF. However, the pathophysiological link between hypertension and AF is unclear. Nevertheless, this can be explained by the hemodynamic changes of the left atrium secondary to long standing hypertension, resulting in elevated left atrium pressure and subsequently left atrial enlargement. Moreover, the activation of renin-angiotensin-aldosterone system (RAAS) activation in patients with hypertension induces left atrial fibrosis and conduction block in the left atrium, resulting in the development of AF. Accordingly, recent studies have shown that effective blockage of RAAS by angiotensin converting enzyme inhibitors or angiotensin receptor antagonist may be effective in both primary and secondary prevention of AF in patients with hypertension, although with controversies. In addition, optimal antithrombotic therapy, blood pressure control as well as rate control for AF are key to the management of patients with AF.Journal of Human Hypertension advance online publication, 1 December 2011; doi:10.1038/jhh.2011.105. |
Persistent Identifier | http://hdl.handle.net/10722/135236 |
ISSN | 2023 Impact Factor: 2.7 2023 SCImago Journal Rankings: 0.753 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lau, YF | en_HK |
dc.contributor.author | Yiu, KH | en_HK |
dc.contributor.author | Siu, CW | en_HK |
dc.contributor.author | Tse, HF | en_HK |
dc.date.accessioned | 2011-07-27T01:30:24Z | - |
dc.date.available | 2011-07-27T01:30:24Z | - |
dc.date.issued | 2012 | en_HK |
dc.identifier.citation | Journal Of Human Hypertension, 2012, v. 26 n. 10, p. 563-569 | en_HK |
dc.identifier.issn | 0950-9240 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/135236 | - |
dc.description.abstract | Hypertension is one of the most important risk factors associated with atrial fibrillation (AF) and increased the risk of cardiovascular events in patients with AF. However, the pathophysiological link between hypertension and AF is unclear. Nevertheless, this can be explained by the hemodynamic changes of the left atrium secondary to long standing hypertension, resulting in elevated left atrium pressure and subsequently left atrial enlargement. Moreover, the activation of renin-angiotensin-aldosterone system (RAAS) activation in patients with hypertension induces left atrial fibrosis and conduction block in the left atrium, resulting in the development of AF. Accordingly, recent studies have shown that effective blockage of RAAS by angiotensin converting enzyme inhibitors or angiotensin receptor antagonist may be effective in both primary and secondary prevention of AF in patients with hypertension, although with controversies. In addition, optimal antithrombotic therapy, blood pressure control as well as rate control for AF are key to the management of patients with AF.Journal of Human Hypertension advance online publication, 1 December 2011; doi:10.1038/jhh.2011.105. | en_HK |
dc.language | eng | en_US |
dc.publisher | Nature Publishing Group. The Journal's web site is located at http://www.nature.com/jhh | en_HK |
dc.relation.ispartof | Journal of Human Hypertension | en_HK |
dc.subject | atrial fibrillation | - |
dc.subject | prevention | - |
dc.subject | renin-angiotensin-aldosterone system | - |
dc.title | Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications | en_HK |
dc.type | Article | en_HK |
dc.identifier.email | Yiu, KH:khkyiu@hku.hk | en_HK |
dc.identifier.email | Siu, CW:cwdsiu@hkucc.hku.hk | en_HK |
dc.identifier.email | Tse, HF:hftse@hkucc.hku.hk | en_HK |
dc.identifier.authority | Yiu, KH=rp01490 | en_HK |
dc.identifier.authority | Siu, CW=rp00534 | en_HK |
dc.identifier.authority | Tse, HF=rp00428 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1038/jhh.2011.105 | en_HK |
dc.identifier.pmid | 205359 | - |
dc.identifier.scopus | eid_2-s2.0-84866393077 | en_HK |
dc.identifier.hkuros | 187315 | en_US |
dc.identifier.isi | WOS:000308688700001 | - |
dc.publisher.place | United Kingdom | en_HK |
dc.identifier.scopusauthorid | Lau, YF=54408995100 | en_HK |
dc.identifier.scopusauthorid | Yiu, KH=35172267800 | en_HK |
dc.identifier.scopusauthorid | Siu, CW=7006550690 | en_HK |
dc.identifier.scopusauthorid | Tse, HF=7006070805 | en_HK |
dc.identifier.citeulike | 10092228 | - |
dc.identifier.issnl | 0950-9240 | - |